Johanna Rodriguez
Payments from drug & device makers
Across 86 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$379
- Novo Nordisk$225
- Amgen$157
- Bayer$125
- Lilly USA, LLC$125
- Sumitomo Pharma America, Inc.$82
- plus $695 from 17 others
What the payments were for
- Food & beverage$1,77699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $379 |
| Novo Nordisk | 12 | $225 |
| Amgen | 8 | $157 |
| Bayer | 6 | $125 |
| Lilly USA, LLC | 6 | $125 |
| Sumitomo Pharma America, Inc. | 3 | $82 |
| Novartis | 5 | $82 |
| Boehringer Ingelheim | 4 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Exact Sciences | 2 | $58 |
| Hologic Sales And Service, LLC | 2 | $49 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Johnson & Johnson | 2 | $38 |
| Pfizer | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Ardelyx, Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Shield Therapeutics Inc | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
How this compares
$1,788 in reported general payments places this provider in the 90th percentile of 713 family providers in New Hampshire.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 55 | $47,182 |
| JardianceEmpagliflozin | 54 | $41,771 |
| OzempicSemaglutide | 41 | $40,285 |
| TrulicityDulaglutide | 26 | $31,794 |
| EliquisApixaban | 19 | $14,420 |
| XareltoRivaroxaban | 13 | $12,229 |
| TradjentaLinagliptin | 14 | $9,496 |
| LinzessLinaclotide | 14 | $9,096 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,465 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $3,739 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $2,556 |
| VascepaIcosapent Ethyl | 18 | $2,353 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $1,918 |
| Alcohol PadsAlcohol Antiseptic Pads | 34 | $1,718 |
| Rosuvastatin Calcium | 68 | $1,653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $81 | $51,26768 claims |
| Novo NordiskOzempic | $225 | $40,28541 claims |
| Lilly USA, LLCTrulicity | $125 | $31,79426 claims |
| PfizerEliquis | $36 | $14,42019 claims |
| Johnson & JohnsonXarelto | $38 | $12,22913 claims |
| AbbVieLinzess | $379 | $9,09614 claims |
| Sanofi-aventis U.S. LLCLantus | $77 | $1,53217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 713 family providers in New Hampshire.
Other family in Bow
- Brant OliverConcord$839K
- Tara Delle ChiaieHampton$548K
- Wendy WrightAmherst$447K
- Kathleen ClarkKeene$199K
- Richard CareyNashua$51K
- Summer BellDerry$16K
- Laura HudsonDover$14K
- Debra KrisonNorth Hampton$13K
- Michelle WhiteBedford$9K
- Cassandra CavanaughDover$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.